The International Stem Cell Corp. is a
fast growing North American biotechnology company focused on developing stem
cell based therapies and biomedical products. The company has developed an
influential new stem cell technology called parthenogenesis that promises to
substantially improve the field of regenerative medicine by addressing the
problem of immune-rejection.
As part of its therapeutic pipeline,
ISCO’s scientists are focused on using the stem cells developed to treat
diseases of the eye, liver and central nervous system, in areas where cell
therapy has been clinically proven yet treatment options are limited by the
availability of safe immune-matched human cells or tissue. The company’s lead
development candidate is a human neural stem cell product to treat Parkinson’s
disease (PD). Preclinical safety and efficacy data was recently presented at
the annual meeting of the Society for Neuroscience And a Phase I/IIa clinical
study is expected to begin in the near future. In the trail ISCO will treat people
with moderate Parkinson’s with a one-time transplant of neural stem cells. In
animal studies the cells have been shown to be safe and also be able to reverse
some of the symptoms of the disease. Interim results from this clinical trial
could be available as early as the end of this year. The idea that a one-time
injection of new cells can “cure” Parkinson’s disease has the potential to
revolutionize the field. The Company also recently announced encouraging
results from a study using the same neural stem cells to treat stroke.
With parthenogenesis, ISCO has developed
a proprietary technique for creating histocompatible stem cells (hpSC).
Parthenogenesis uses unfertilized human eggs to create parthenogenetic stem
cells that can be immune-matched to millions of people. This process results in
the cells inheriting a matching set of human leukocyte antigen (HLA) genes,
which drastically reduces the possibility of the resulting cells being rejected
by an individual’s immune system after transplantation, making a single cell
line suitable for treating millions of individuals of differing genders, ages
and racial background. hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos, and a fairly small number of such cell
lines could provide enough immune-matched cells to cover a sizeable percentage
of the world’s population.
Histocompatible stem cells offer the
potential to create the first true stem cell bank, UniStemCell. This could be
the foundation of ISCO’s research as well as the life science industry’s first
collection of non-embryonic histocompatible human stem cells for research and
commercial use.
In mid-March 2015, ISCO revealed that
the Japan Patent Office had granted it a patent that covered its methods of
making a bank of human stem cells from parthenogenetically activated eggs. The
new patent extends the reach of the company’s intellectual property portfolio
beyond the United States and European Union making it a very appealing partner.
Over time, ISCO could generate revenue
from universal stem cell bank franchises across populations and from scientists
accessing these lines. This would also provide additional validation of the
hpSC lines as they will be tested and developed by others across a range of
potential applications and, longer-term, will provide the company with
royalties from the sales of each successful, hpSC-derived cellular therapeutic.
For more information, visit
www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment